TherapeuticsMD Inc(TXMD) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.

Current Price

$1.09

RSI

36.166

Beta:

1.955874

March 04, 2021
237.8M
-30.8M

46.185 %
-45.223 %
14.864 %
-42.808 %

$36,015,858
$22,207,090
$11,421,626
$16,777,713
$19,356,450
$20,142,898
62.182 %
94.430 %
-46.894 %
-15.370 %
-4.063 %

$-233,074,110
$-215,773,944
$-173,912,603
$-30,225,380
$-89,875,459
$-85,077,024
-7.423 %
-19.401 %
-82.620 %
197.351 %
-5.339 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.